Charles River Laboratories Intl. Inc vs Mondaycom Ltd — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Mondaycom Ltd trades at $88.96 (market cap $3.76B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 3.8× Mondaycom Ltd's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Mondaycom Ltd for 16 Days on average.
| CRL | MNDY | |
|---|---|---|
Market Cap | $14.23B | $3.76B |
Volume | 1,176,885 | 836,200 |
Sector | Health | Technology |
52-Week High | $310.77 | $205.24 |
52-Week Low | $149.93 | $58.81 |
Typical Hold Time | 33 Days | 16 Days |
Enterprise Value | $17.06B | $2.92B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
Monday.com (MNDY) trades at $88.91, up 6.47% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with revenue growth to $1.23B in 2025, net income of $118.74M, and consistent earnings beats. Recent news highlights AI integration at Elevate '26 conference and inclusion in growth stock lists. Analyst consensus remains strongly bullish with 17 buy ratings and $108.64 price target.
Outlook remains positive given strong enterprise client growth and AI adoption, though elevated valuation ratios (P/E 37.69) and competitive pressures from Meta's enterprise push present risks. The stock offers growth potential but requires monitoring of profit margin sustainability and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →